A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy

Inclusion criteria

• patients or their guardians are able to provide a written informed consent
• participants undergo upper gastrointestinal endoscopy
• ≥18 years old, male or female
• 18 kg/m2≤bmi≤30kg/m2

Exclusion criteria

• Subjects to be intubated (including laryngeal mask placement);
• Complex endoscopic diagnosis and treatment operations are required;
• Severe cardiovascular disease within 6 months prior to signing the ICF;
• Heart rate < 50 beats/min during screening period;
• Subjects with poor blood pressure control during screening;
• Severe arrhythmias or heart disease; the circulatory system is unstable;
• Subjects with a history of severe cardiovascular disease, or cerebrovascular disease, or neurological disease, or mental illness
• Subjects with a history of drug abuse;
• Abnormal values of the laboratory examination;
• Allergic to relevant drugs ingredient or component;
• Pregnant or nursing women;
• Subjects who has participated in clinical trials of other interventions recently;
• Other conditions deemed unsuitable to be included.